Two-Drug Combo Targets Shape-Shifting Prostate Cancer That Evades Standard Treatment
University of Michigan researchers found a two-drug strategy that reverses cellular identity changes in treatment-resistant prostate cancer, sharply slowing tumor growth.
Summary
Prostate cancer is the second leading cause of cancer-related death in men. A major challenge is that tumors often develop resistance to hormone-blocking drugs by changing their cellular identity — a process called transdifferentiation. Researchers at the University of Michigan have now identified a two-drug approach that attacks this process from two angles. One drug class, BET bromodomain inhibitors, disrupts the pathways cancer cells use to switch identities. A second class, DNMT inhibitors, reactivates glandular genes that cancer cells had silenced. Together in preclinical experiments, the combination reversed many of these identity changes and significantly slowed tumor growth. The researchers believe the strategy may also apply to other cancers that use similar escape mechanisms, including lung and pancreatic cancers.
Detailed Summary
Prostate cancer affects roughly one in eight men over their lifetime, and while many survive, metastatic prostate cancer remains the second leading cause of cancer death among men in the United States. Standard treatment relies on androgen receptor inhibitors that block testosterone-driven tumor growth, but nearly all patients eventually develop resistance — making new treatment strategies urgently needed.
A key mechanism behind this resistance is transdifferentiation, a process in which cancer cells shed their original glandular identity and adopt stem-cell-like characteristics, allowing them to bypass hormone-blocking drugs entirely. University of Michigan researchers publishing in JCI Insight traced this identity switch to the loss of two tumor-suppressor genes, TP53 and RB1, and mapped the downstream pathway changes this triggers.
The team identified two complementary vulnerabilities. BET bromodomain inhibitors, drugs previously shown to interfere with alternative identity programs in cancer cells, slowed tumor growth in cell lines but could not kill the cancer on their own. Adding DNMT inhibitors — drugs that reactivate silenced genes — restored the glandular gene expression that had been switched off during transdifferentiation. Together, the two-drug combination reversed many of the identity changes and sharply reduced tumor growth in preclinical models.
The researchers believe the approach may extend well beyond prostate cancer. Transdifferentiation is also observed in treatment-resistant lung and pancreatic cancers, suggesting that dual targeting of identity-switching pathways could become a broader oncology strategy.
Important caveats apply: these findings are preclinical, based on cell lines and laboratory models rather than human trials. Translating this into clinical benefit will require safety and efficacy testing in patients. Nonetheless, the work provides a mechanistic rationale for a combination therapy strategy in one of the most lethal and treatment-resistant cancer subtypes.
Key Findings
- Loss of TP53 and RB1 genes drives prostate cancer cells to change identity, evading androgen receptor inhibitors.
- BET bromodomain inhibitors slow growth of treatment-resistant prostate cancer cells but cannot eliminate them alone.
- Adding DNMT inhibitors reactivates silenced glandular genes, complementing BET inhibitors in preclinical models.
- The two-drug combination reversed cellular identity changes and sharply slowed tumor growth in lab experiments.
- The strategy may also apply to transdifferentiation-driven resistance in lung and pancreatic cancers.
Methodology
This is a news report summarizing a peer-reviewed study published in JCI Insight from the University of Michigan. Evidence is preclinical, based on prostate cancer cell lines and laboratory models. No human clinical trial data are reported.
Study Limitations
All findings are from preclinical cell-line experiments; efficacy and safety in humans remain unproven. The article is a summary and does not detail dosing, sequencing, or toxicity data. Readers should consult the primary JCI Insight paper for full methodology and statistical results.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: